IDXG INTERPACE BIOSCIENCES, INC.
Company Updates ·
The preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025.
The split takes effect August 27, 2026 and reduces outstanding shares from approximately 27.7 million to approximately 5.5 million, aimed at Nasdaq's minimum bid price requirement.
Revenue was $9.1 million, down slightly from the prior-year quarter as reported, while income from continuing operations was $0.3 million and thyroid revenue rose 9%.
Revenue was $9.0 million, down 22% from the prior-year quarter as reported and up 14% on a pro forma basis, and the company reaffirmed its 2026 thyroid growth guidance.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $642,000 | $676,000 |
| Net income (loss) | $24.6 million | $6.7 million |
| Cash from operations | $5.8 million | $4.6 million |
| Cash and equivalents | $2.5 million | $1.5 million |
Our latest story on this, dated Aug 26, 2026: "Interpace Biosciences sets 1-for-5 reverse stock split to support Nasdaq bid". The story links the filing or release it is based on. Read the story.
INTERPACE BIOSCIENCES, INC. trades under the ticker IDXG on OTC.
INTERPACE BIOSCIENCES, INC. is listed on OTC.
Our directory records INTERPACE BIOSCIENCES, INC. under United States.
aibio.space lists INTERPACE BIOSCIENCES, INC. among 2,820 public biotech companies and publishes its news here as stories appear.
INTERPACE BIOSCIENCES, INC. reported net income of $24.6 million for the fiscal year ended Dec 31, 2025, and generated $5.8 million of cash from operations, per its annual report to the SEC.
$642,000 in the fiscal year ended Dec 31, 2025, per its annual report.
$2.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on INTERPACE BIOSCIENCES, INC., dated Oct 14, 2026: "Interpace Biosciences expects third quarter revenue of $10.1 million to $10.4 million". The preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025. Source.
Press Follow on this page to add INTERPACE BIOSCIENCES, INC. to your Following list, or subscribe to the aibio.space newsletter. We have published 4 stories naming INTERPACE BIOSCIENCES, INC. so far, in Company Updates, Listings.
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Filed documents for a merger or acquisition. SEC Form PREM14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio